Skip to main content
. Author manuscript; available in PMC: 2020 Jul 9.
Published in final edited form as: Vaccine. 2019 Jun 7;37(30):4040–4046. doi: 10.1016/j.vaccine.2019.06.001

Table 4.

Multivariable logistic regression to examine the effect of time and vaccination on vaccine-specific HPV types (6, 11, 16, 18) detected through vaginal swab during post-licensure years, NHANES data 2007–2014 (N=3,188)a

Model 1 b Model 2 c Model 3 d
PaOR (95% CI) PaOR (95% CI) PaOR (95% CI)
Region
 Northeast 0.95 (0.53–1.71) 0.92 (0.54–1.59) 0.96 (0.54–1.72)
 Midwest 1.60 (0.99–2.56) 1.55 (0.97–2.46) 1.54 (0.97–2.46)
 South 1.38 (0.91–2.10) 1.38 (0.92–2.07) 1.32 (0.87–1.99)
 West Reference Reference Reference
NHANES cycles
 2007–2008 Reference Reference
 2009–2010 0.76 (0.54–1.06) 0.80 (0.57–1.12)
 2011–2012 0.48 (0.32–0.71) 0.54 (0.36–0.82)
 2013–2014 0.38 (0.24–0.62) 0.48 (0.30–0.77)
HPV vaccination
 0 doses Reference
 1+ doses 0.48 (0.30–0.77)
a

Vaccine-specific HPV types include 4 HPV types (6, 11, 16, and 18) that the quadrivalent HPV vaccine protects against.

b

Model 1 controlled for age, race/ethnicity, and number of lifetime male sex partners.

c

Model 2 controlled for variables from Model 1 + NHANES cycles in post-licensure period.

d

Model 3 controlled for variables from Model 2 + HPV vaccine initiation.

All models controlled for age, race/ ethnicity, and number of male sexual partners in the past year.

HPV=human papillomavirus; NHANES=National Health and Nutrition Examination Survey